High doses of GHB may lead to nausea, dizziness, drowsiness, agitation, visual disturbances, depressed breathing, amnesia, unconsciousness, and death in some cases.
Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Hydrocodone | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Magnesium sulfate | The therapeutic efficacy of gamma-Hydroxybutyric acid can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | gamma-Hydroxybutyric acid may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Mirtazapine | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Orphenadrine | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Pramipexole | gamma-Hydroxybutyric acid may increase the sedative activities of Pramipexole. |
| Ropinirole | gamma-Hydroxybutyric acid may increase the sedative activities of Ropinirole. |
| Rotigotine | gamma-Hydroxybutyric acid may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with gamma-Hydroxybutyric acid. |
| Suvorexant | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Thalidomide | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with gamma-Hydroxybutyric acid. |
| Ethanol | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Alaproclate. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with gamma-Hydroxybutyric acid. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with gamma-Hydroxybutyric acid. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with gamma-Hydroxybutyric acid. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with gamma-Hydroxybutyric acid. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with gamma-Hydroxybutyric acid. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with gamma-Hydroxybutyric acid. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with gamma-Hydroxybutyric acid. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with gamma-Hydroxybutyric acid. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with gamma-Hydroxybutyric acid. |
| Pizotifen | The risk or severity of CNS depression can be increased when gamma-Hydroxybutyric acid is combined with Pizotifen. |
| Dosulepin | The risk or severity of CNS depression can be increased when gamma-Hydroxybutyric acid is combined with Dosulepin. |
| Zopiclone | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with gamma-Hydroxybutyric acid. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with gamma-Hydroxybutyric acid. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with gamma-Hydroxybutyric acid. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with gamma-Hydroxybutyric acid. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with gamma-Hydroxybutyric acid. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with gamma-Hydroxybutyric acid. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with gamma-Hydroxybutyric acid. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with gamma-Hydroxybutyric acid. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with gamma-Hydroxybutyric acid. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with gamma-Hydroxybutyric acid. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with gamma-Hydroxybutyric acid. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with gamma-Hydroxybutyric acid. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with gamma-Hydroxybutyric acid. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with gamma-Hydroxybutyric acid. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with gamma-Hydroxybutyric acid. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with gamma-Hydroxybutyric acid. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with gamma-Hydroxybutyric acid. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with gamma-Hydroxybutyric acid. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with gamma-Hydroxybutyric acid. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with gamma-Hydroxybutyric acid. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with gamma-Hydroxybutyric acid. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with gamma-Hydroxybutyric acid. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with gamma-Hydroxybutyric acid. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with gamma-Hydroxybutyric acid. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with gamma-Hydroxybutyric acid. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with gamma-Hydroxybutyric acid. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with gamma-Hydroxybutyric acid. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with gamma-Hydroxybutyric acid. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with gamma-Hydroxybutyric acid. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with gamma-Hydroxybutyric acid. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with gamma-Hydroxybutyric acid. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with gamma-Hydroxybutyric acid. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with gamma-Hydroxybutyric acid. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with gamma-Hydroxybutyric acid. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with gamma-Hydroxybutyric acid. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with gamma-Hydroxybutyric acid. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with gamma-Hydroxybutyric acid. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with gamma-Hydroxybutyric acid. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with gamma-Hydroxybutyric acid. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with gamma-Hydroxybutyric acid. |
| Alprazolam | The risk or severity of CNS depression can be increased when Alprazolam is combined with gamma-Hydroxybutyric acid. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with gamma-Hydroxybutyric acid. |
| Loxapine | The risk or severity of CNS depression can be increased when Loxapine is combined with gamma-Hydroxybutyric acid. |